TAIHO PHARMA ASIA PACIFIC PTE. LTD.

**1 INDICATIONS AND USAGE** **1.1 Metastatic Colorectal Cancer** Lonsurf® is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. **1.2 Metastatic Gastric Cancer** Lonsurf® is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma who have been previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neutargeted therapy.

**INDICATIONS** - Post-operative adjuvant chemotherapy for locally advanced (stage II (excluding T1), IIIA or IIIB) gastric cancer - For the treatment of locally advanced or metastatic adenocarcinoma of the pancreas - For the treatment of locally advanced or metastatic non-small cell lung cancer in patients who have been previously treated with platinum-based chemotherapy

<p><strong>INDICATIONS</strong></p> <ul class="dash"> <li>Post-operative adjuvant chemotherapy for locally advanced (stage II (excluding T1), IIIA or IIIB) gastric cancer</li> <li>For the treatment of locally advanced or metastatic adenocarcinoma of the pancreas</li> <li>For the treatment of locally advanced or metastatic non-small cell lung cancer in patients who have been previously treated with platinum-based chemotherapy</li> </ul>